Coherus Biosciences Reports Q1 2026 Loss Above Expectations
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Biosciences reported a Q1 2026 loss of $0.25 per share, missing the consensus estimate of $0.18 loss per share
- Compared to the first quarter of 2025 with a $0.35 loss per share, the company's loss position improved
- The biotechnology company focuses on the development of biosimilars and innovative oncology drugs for cancer treatment
- Coherus expects increasing revenue growth for its drug LOQTORZI for the treatment of nasopharyngeal carcinoma over the remaining quarters of 2026
- The company plans several clinical data publications from its oncology pipeline for the remainder of 2026
Coherus Biosciences (NASDAQ: CHRS) reported on May 11, 2026 a loss of $0.25 per share for the first quarter of 2026, missing the consensus estimate of $0.18 loss per share. The Redwood City, California-based biotechnology company thus fell significantly short of analyst expectations.
Quarterly Results Below Expectations
Compared to the prior year quarter, however, the company's loss position improved: In the first quarter of 2025, Coherus had reported a loss of $0.35 per share. The company also missed analyst revenue expectations in the reporting quarter, as shown in the figures published on May 11, 2026.
Coherus Biosciences specializes in the development and commercialization of cancer therapies. The company particularly focuses on biosimilars – biotechnologically manufactured follow-on products of already approved biologics – as well as innovative oncology drugs.
Outlook on LOQTORZI Revenue Growth
In the conference call on quarterly results on May 11, 2026, the company stated that it expects increasing revenue growth for LOQTORZI over the remaining quarters of 2026. LOQTORZI is a drug for the treatment of nasopharyngeal carcinoma – a cancer form that occurs in the upper part of the throat behind the nose.
In addition to revenue expectations for LOQTORZI, Coherus announced that several clinical data publications from its oncology pipeline are planned for the remainder of 2026. These data publications could represent important milestones for the further development of the product portfolio.
Company Context and Earlier Announcements
On July 31, 2025, Coherus Biosciences announced that financial results for the second quarter of 2025 would be released on August 7, 2025 after market close. This announcement followed the standard communication schedule of publicly traded U.S. companies.
The company also operates under the designation Coherus Oncology and has now concentrated its business activities entirely on the oncology area, after originally developing biosimilars in other therapeutic areas as well.